Nexstim
9.16
EUR
+0.44 %
Corporate customer
NXTMH
First North Finland
Medical Equipment & Services
Health Care
5,374 following
+0.44%
+15.95%
+6.51%
+52.67%
+205.33%
+264.94%
+110.57%
+459.76%
-98.49%
Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.
Read moreMarket cap
65.6M EUR
Turnover
33.27K EUR
P/E (adj.) (24e)
-256.1
EV/EBIT (adj.) (24e)
-450.37
P/B (24e)
25.56
EV/S (24e)
8.14
Dividend yield-% (24e)
-
Financial calendar
27.2
2025
Annual report '24
Risk
Business risk
Valuation risk
Low
High
ShowingAll content types
Nexstim Receives NBS 5 System Order from New Customer in Ohio, United States
Nexstim: Good end to a strong year
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Nexstim Plc: Henri Hannula appointed as CCO
Nexstim Plc’s Financial Information and Annual General Meeting in 2025
Nexstim Plc: Managers’ Transactions, Hannula
Nexstim Plc: Conversion of stock options 2023A to stock options 2023B and 2023C
Delve Psychiatry in Nevada, United States Orders Nexstim NBS 5+ System
Nexstim Receives NBS 6 Order from University Hospital in California
Distributor Orders Two Nexstim NBS 5 Systems
Finnish University Hospital Orders Nexstim NBS System 5
Nexstim Receives an Upgrade Order from a German University Hospital
US Customer Orders Nexstim NBS System 5
Nexstim Plc’s New Shares Have Been Registered with the Finnish Trade Register
Nexstim Plc: Managers’ Transactions, Forss
Nexstim Plc: Managers’ Transactions, Niemistö
